Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial
No abstract for this item (typically a correction, editorial or news piece — the publisher provides none)